Anticancer CAS 1009119-64-5 Daclatasvir Purity Daclatasvir Powder Daclatasvir

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung Daclatasvir
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• Purity: >99%
• Product Name: Daclatasvir
• Name: Daclatasvir Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 1009119-64-5
• Mf: C40h50n8o6
• MW: 738.88
• Boiling Point: 1071.239
• Density: 1.25
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 1000kg/Month

Product Description

Anticancer CAS 1009119-64-5 Daclatasvir Purity Daclatasvir Powder Daclatasvir

Product Description

Product Details

 

Product name	Daclatasvir
Cas number	1009119-64-5
Apperance	White powder
Boiling point	1071.239 °C at 760 mmHg
MF	C40H50N8O6
Density	1.25
Refractive index	1.595
MW	738.875

 

Daclatasvir is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection.Hepatitis C is an infectious liver disease caused by infection with Hepatitis C Virus (HCV). 
Daclatasvir was discovered as a first-in-class inhibitor of the non-structural viral protein 5A (NS5A), a phosphoprotein that plays an important role in hepatitis C replication.

Application&Function

Daclatasvir (Daklinza) has obtained "priority review" status, combined with sorafenib for the treatment of genotype III adult patients with chronic hepatitis C. Daklinza has been the first drug that has been proved of being effective in the treatment of genotype III hepatitis C virus infection without the co-administration with interferon or ribavirin. Interferon and ribavirin are two drugs approved by FDA for the treatment of hepatitis C virus infection. Hepatitis C is a viral disease that can cause inflammation of the liver, resulting in decreased liver function or liver failure. Most patients infected with hepatitis C have no symptoms until liver damage becomes apparent, which may take several years.
Globally, genotype III hepatitis C is the second most common genotype of hepatitis C after genotype 1 hepatitis C and is considered to be one of the most refractory genotype diseases. Daklinza is a pan-genotype NS5A replication complex inhibitor, with efficacy of inhibition of RNA replication and viral assembly, dual antiviral effect.

Specification